Biotech Values

[jq1234]

Do you see the potential for NKTR118 being a sufficient overhang for PGNX for some time?

Not really. NKTR118 had been known quantity for sometime. Oral Relistor is still ahead of NKTR118 in development. The market is big enough for two oral products. The key to PGNX is to get Relistor subc approved for general population, and Salix does a better job than Wyeth in generating sales. If there weren't oral Relistor, NKTR118 definitely would have pose serious risk on Relistor subc.